Similar articles

• CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment.

  Metro G, Lunardi G, Floridi P, Pascali JP, Marcomigni L, Chiari R, Ludovini V, Crinò L, Gori S. Metro G, et al. J Thorac Oncol. 2015 May;10(5):e26-e27. doi: 10.1097/JTO.0000000000000468. J Thorac Oncol. 2015. PMID: 25898960 No abstract available.
• Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

  Rodig SJ, Shapiro GI. Rodig SJ, et al. Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Curr Opin Investig Drugs. 2010. PMID: 21154129 Review.
• ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.

  Ahn HK, Han B, Lee SJ, Lim T, Sun JM, Ahn JS, Ahn MJ, Park K. Ahn HK, et al. Lung Cancer. 2012 May;76(2):253-4. doi: 10.1016/j.lungcan.2012.02.003. Epub 2012 Mar 3. Lung Cancer. 2012. PMID: 22385925
• Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.

  Kijima T, Takeuchi K, Tetsumoto S, Shimada K, Takahashi R, Hirata H, Nagatomo I, Hoshino S, Takeda Y, Kida H, Goya S, Tachibana I, Kawase I. Kijima T, et al. Cancer Sci. 2011 Aug;102(8):1602-4. doi: 10.1111/j.1349-7006.2011.01970.x. Cancer Sci. 2011. PMID: 21767331
• Crizotinib (xalkori) for non-small cell lung cancer.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2012 Feb 6;54(1383):11-2. Med Lett Drugs Ther. 2012. PMID: 22354221 Review. No abstract available.